| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 10 | 2023 | 36 | 3.270 |
Why?
|
| Cerebellar Neoplasms | 9 | 2023 | 36 | 3.230 |
Why?
|
| Brain Neoplasms | 36 | 2022 | 763 | 3.110 |
Why?
|
| Brain Stem Neoplasms | 12 | 2022 | 17 | 2.790 |
Why?
|
| Astrocytoma | 17 | 2022 | 82 | 2.660 |
Why?
|
| Glioma | 18 | 2022 | 285 | 2.650 |
Why?
|
| Child | 57 | 2023 | 6926 | 1.290 |
Why?
|
| Neoplasm Recurrence, Local | 19 | 2023 | 1313 | 1.270 |
Why?
|
| Child, Preschool | 44 | 2022 | 3611 | 1.130 |
Why?
|
| Phacoemulsification | 6 | 2011 | 16 | 0.940 |
Why?
|
| Tomography, Optical Coherence | 4 | 2011 | 130 | 0.900 |
Why?
|
| Medicare Part C | 1 | 2022 | 6 | 0.890 |
Why?
|
| Fee-for-Service Plans | 1 | 2022 | 30 | 0.870 |
Why?
|
| Cornea | 3 | 2011 | 69 | 0.850 |
Why?
|
| Viral Vaccines | 1 | 2022 | 43 | 0.840 |
Why?
|
| Humans | 116 | 2023 | 86601 | 0.830 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 153 | 0.830 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 12 | 0.830 |
Why?
|
| Stem Cell Transplantation | 4 | 2011 | 183 | 0.810 |
Why?
|
| Plasma Exchange | 1 | 2021 | 29 | 0.810 |
Why?
|
| Dacarbazine | 3 | 2016 | 102 | 0.790 |
Why?
|
| Indians, North American | 2 | 2013 | 48 | 0.780 |
Why?
|
| Fuchs' Endothelial Dystrophy | 2 | 2010 | 11 | 0.780 |
Why?
|
| Vaccination | 2 | 2023 | 254 | 0.770 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 2 | 2010 | 19 | 0.760 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2011 | 138 | 0.740 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 202 | 0.710 |
Why?
|
| Vena Cava Filters | 1 | 2021 | 96 | 0.700 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 111 | 0.680 |
Why?
|
| Combined Modality Therapy | 14 | 2023 | 1685 | 0.680 |
Why?
|
| Cardiovascular Diseases | 4 | 2014 | 827 | 0.670 |
Why?
|
| Male | 70 | 2022 | 40956 | 0.660 |
Why?
|
| Macular Edema | 3 | 2009 | 50 | 0.650 |
Why?
|
| Chemoradiotherapy | 4 | 2017 | 301 | 0.640 |
Why?
|
| Neoplasms | 9 | 2023 | 2897 | 0.640 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 221 | 0.640 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 243 | 0.630 |
Why?
|
| Antineoplastic Agents | 13 | 2020 | 2357 | 0.620 |
Why?
|
| Adolescent | 38 | 2020 | 8979 | 0.610 |
Why?
|
| Methionine | 1 | 2017 | 66 | 0.600 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2013 | 292 | 0.600 |
Why?
|
| Female | 67 | 2022 | 44507 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 2436 | 0.540 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2019 | 137 | 0.530 |
Why?
|
| Lens Implantation, Intraocular | 7 | 2011 | 23 | 0.530 |
Why?
|
| Infant | 22 | 2022 | 3045 | 0.510 |
Why?
|
| Mutation | 5 | 2019 | 3967 | 0.480 |
Why?
|
| Glioblastoma | 3 | 2011 | 255 | 0.480 |
Why?
|
| Medicine, Traditional | 1 | 2013 | 8 | 0.470 |
Why?
|
| Licensure | 1 | 2013 | 6 | 0.470 |
Why?
|
| Administration, Metronomic | 1 | 2013 | 2 | 0.470 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2013 | 44 | 0.460 |
Why?
|
| Pons | 2 | 2011 | 24 | 0.450 |
Why?
|
| Oxides | 1 | 2013 | 43 | 0.450 |
Why?
|
| Arsenicals | 1 | 2013 | 48 | 0.440 |
Why?
|
| Endothelial Cells | 10 | 2014 | 428 | 0.440 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2011 | 468 | 0.430 |
Why?
|
| Leukocytes | 1 | 2013 | 202 | 0.420 |
Why?
|
| Hematopoiesis | 1 | 2013 | 163 | 0.420 |
Why?
|
| Cranial Irradiation | 4 | 2016 | 36 | 0.410 |
Why?
|
| Retrospective Studies | 16 | 2022 | 8475 | 0.410 |
Why?
|
| Gliosarcoma | 1 | 2011 | 7 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 266 | 0.400 |
Why?
|
| Microvessels | 1 | 2011 | 70 | 0.390 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 357 | 0.390 |
Why?
|
| Aged | 21 | 2022 | 18402 | 0.380 |
Why?
|
| Survival Rate | 11 | 2017 | 1860 | 0.380 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 689 | 0.380 |
Why?
|
| Young Adult | 18 | 2020 | 5974 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-myc | 5 | 2019 | 120 | 0.370 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2008 | 9 | 0.370 |
Why?
|
| Bone Marrow | 2 | 2011 | 435 | 0.370 |
Why?
|
| Aqueous Humor | 1 | 2009 | 23 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2010 | 407 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2019 | 589 | 0.360 |
Why?
|
| Stem Cells | 6 | 2013 | 351 | 0.350 |
Why?
|
| United States | 7 | 2022 | 6665 | 0.350 |
Why?
|
| Multiple Myeloma | 2 | 2011 | 307 | 0.350 |
Why?
|
| Diabetic Retinopathy | 2 | 2009 | 87 | 0.350 |
Why?
|
| Supratentorial Neoplasms | 2 | 2008 | 10 | 0.340 |
Why?
|
| Treatment Outcome | 19 | 2022 | 7988 | 0.340 |
Why?
|
| Flow Cytometry | 8 | 2013 | 679 | 0.330 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 3636 | 0.320 |
Why?
|
| Prognosis | 16 | 2018 | 3674 | 0.320 |
Why?
|
| Postoperative Complications | 4 | 2011 | 2207 | 0.320 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 878 | 0.310 |
Why?
|
| Middle Aged | 23 | 2022 | 25017 | 0.300 |
Why?
|
| Cytokines | 1 | 2011 | 776 | 0.300 |
Why?
|
| Lymphoma | 3 | 2010 | 262 | 0.300 |
Why?
|
| Life Style | 1 | 2008 | 189 | 0.300 |
Why?
|
| Depressive Disorder | 1 | 2008 | 218 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2020 | 3352 | 0.290 |
Why?
|
| Social Environment | 1 | 2008 | 188 | 0.290 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 151 | 0.280 |
Why?
|
| Risk Factors | 10 | 2021 | 5416 | 0.280 |
Why?
|
| Bone Marrow Cells | 5 | 2011 | 253 | 0.280 |
Why?
|
| Adult | 27 | 2022 | 25640 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 592 | 0.280 |
Why?
|
| Radiotherapy Dosage | 6 | 2013 | 468 | 0.270 |
Why?
|
| Pilot Projects | 2 | 2023 | 839 | 0.270 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 1169 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 5 | 2014 | 353 | 0.260 |
Why?
|
| Transplantation, Autologous | 6 | 2022 | 330 | 0.260 |
Why?
|
| Rectal Neoplasms | 4 | 2007 | 116 | 0.250 |
Why?
|
| Biomarkers | 6 | 2023 | 1718 | 0.240 |
Why?
|
| Depression | 1 | 2008 | 473 | 0.240 |
Why?
|
| Platelet Count | 2 | 2021 | 92 | 0.240 |
Why?
|
| Infratentorial Neoplasms | 3 | 2018 | 3 | 0.240 |
Why?
|
| Brain | 5 | 2018 | 2216 | 0.240 |
Why?
|
| Temporal Lobe | 2 | 2016 | 172 | 0.240 |
Why?
|
| Oligodendroglioma | 2 | 2014 | 45 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2014 | 311 | 0.230 |
Why?
|
| Ipilimumab | 1 | 2023 | 58 | 0.230 |
Why?
|
| Craniospinal Irradiation | 1 | 2022 | 1 | 0.230 |
Why?
|
| Disease Management | 2 | 2016 | 327 | 0.230 |
Why?
|
| Biomarkers, Tumor | 6 | 2013 | 1464 | 0.220 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2002 | 5 | 0.220 |
Why?
|
| Endothelium, Vascular | 3 | 2014 | 435 | 0.220 |
Why?
|
| Fluvoxamine | 1 | 2022 | 6 | 0.220 |
Why?
|
| Ivermectin | 1 | 2022 | 7 | 0.220 |
Why?
|
| Melanoma, Experimental | 2 | 2014 | 103 | 0.220 |
Why?
|
| Pharmaceutical Services | 1 | 2022 | 9 | 0.220 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2022 | 12 | 0.220 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2002 | 2 | 0.220 |
Why?
|
| Retina | 1 | 2004 | 213 | 0.210 |
Why?
|
| Cataract | 4 | 2010 | 86 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2016 | 930 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 645 | 0.210 |
Why?
|
| Recurrence | 3 | 2023 | 1139 | 0.210 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 11 | 0.210 |
Why?
|
| Technology | 1 | 2022 | 29 | 0.210 |
Why?
|
| Medicare | 2 | 2022 | 406 | 0.210 |
Why?
|
| Meningeal Neoplasms | 2 | 2012 | 61 | 0.200 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 427 | 0.200 |
Why?
|
| Spinal Neoplasms | 2 | 2012 | 50 | 0.200 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2022 | 182 | 0.200 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 177 | 0.200 |
Why?
|
| Cataract Extraction | 2 | 2010 | 31 | 0.190 |
Why?
|
| Everolimus | 1 | 2020 | 40 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 128 | 0.190 |
Why?
|
| Methotrexate | 1 | 2021 | 249 | 0.190 |
Why?
|
| Cerebral Hemorrhage | 2 | 2013 | 325 | 0.190 |
Why?
|
| Endpoint Determination | 1 | 2020 | 60 | 0.190 |
Why?
|
| Oximes | 1 | 2019 | 14 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2018 | 276 | 0.180 |
Why?
|
| Massachusetts | 3 | 2018 | 33 | 0.180 |
Why?
|
| Anterior Eye Segment | 2 | 2010 | 6 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 5 | 2019 | 270 | 0.180 |
Why?
|
| Pediatrics | 3 | 2016 | 344 | 0.180 |
Why?
|
| Mesencephalon | 1 | 2000 | 64 | 0.180 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2013 | 16 | 0.180 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2018 | 67 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2022 | 380 | 0.170 |
Why?
|
| Radiation Injuries | 2 | 2018 | 155 | 0.170 |
Why?
|
| Neuroimaging | 1 | 2020 | 113 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 429 | 0.170 |
Why?
|
| Neovascularization, Physiologic | 2 | 2011 | 133 | 0.170 |
Why?
|
| Animals | 21 | 2017 | 26581 | 0.170 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 1204 | 0.170 |
Why?
|
| Mental Disorders | 2 | 2009 | 371 | 0.170 |
Why?
|
| Imidazoles | 1 | 2019 | 162 | 0.170 |
Why?
|
| Receptor, EphB4 | 2 | 2012 | 24 | 0.170 |
Why?
|
| Brain Ischemia | 2 | 2013 | 398 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2014 | 100 | 0.170 |
Why?
|
| Rituximab | 1 | 2019 | 116 | 0.160 |
Why?
|
| Carcinoma | 1 | 2002 | 436 | 0.160 |
Why?
|
| Prospective Studies | 10 | 2022 | 4210 | 0.160 |
Why?
|
| Ependymoma | 2 | 2012 | 17 | 0.160 |
Why?
|
| Proton Therapy | 1 | 2018 | 27 | 0.160 |
Why?
|
| Ultrasonography | 2 | 2010 | 695 | 0.160 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 1019 | 0.160 |
Why?
|
| Blood Vessels | 3 | 2007 | 94 | 0.160 |
Why?
|
| Corpus Callosum | 1 | 2018 | 56 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 392 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 189 | 0.160 |
Why?
|
| Taxoids | 1 | 2018 | 129 | 0.160 |
Why?
|
| Biphenyl Compounds | 1 | 2017 | 68 | 0.150 |
Why?
|
| Brain Stem | 1 | 2018 | 165 | 0.150 |
Why?
|
| Quinazolines | 2 | 2010 | 220 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 426 | 0.150 |
Why?
|
| Hospitalization | 1 | 2022 | 848 | 0.150 |
Why?
|
| Neurons | 2 | 2018 | 1546 | 0.150 |
Why?
|
| Postoperative Period | 2 | 2010 | 303 | 0.150 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2016 | 3 | 0.150 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2016 | 21 | 0.140 |
Why?
|
| Antigens, CD34 | 3 | 2013 | 158 | 0.140 |
Why?
|
| Cognition | 2 | 2018 | 570 | 0.140 |
Why?
|
| Cell Proliferation | 6 | 2012 | 1578 | 0.140 |
Why?
|
| Community Mental Health Centers | 1 | 1995 | 3 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2022 | 2767 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2017 | 140 | 0.140 |
Why?
|
| Frontal Lobe | 1 | 2016 | 130 | 0.140 |
Why?
|
| Patient Dropouts | 1 | 1995 | 28 | 0.130 |
Why?
|
| Pyridines | 1 | 2017 | 309 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 176 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 155 | 0.130 |
Why?
|
| Histones | 1 | 2017 | 311 | 0.130 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 20 | 0.130 |
Why?
|
| Lymphocyte Depletion | 2 | 2014 | 97 | 0.130 |
Why?
|
| Tissue Distribution | 3 | 2019 | 290 | 0.120 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 206 | 0.120 |
Why?
|
| Activin Receptors, Type I | 1 | 2014 | 12 | 0.120 |
Why?
|
| Cell-Derived Microparticles | 1 | 2014 | 11 | 0.120 |
Why?
|
| Stroke | 2 | 2013 | 965 | 0.120 |
Why?
|
| Infant, Newborn | 3 | 2014 | 2378 | 0.120 |
Why?
|
| Niacinamide | 1 | 2014 | 116 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 938 | 0.120 |
Why?
|
| Interferon-beta | 1 | 2014 | 125 | 0.120 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 113 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 303 | 0.120 |
Why?
|
| Neurofibromin 1 | 1 | 2013 | 8 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2013 | 9 | 0.120 |
Why?
|
| Mice | 14 | 2014 | 11352 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 4 | 2014 | 1376 | 0.120 |
Why?
|
| Hypertension | 1 | 2022 | 1141 | 0.120 |
Why?
|
| Anaplasia | 2 | 2004 | 5 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 1996 | 403 | 0.120 |
Why?
|
| Candidemia | 1 | 2013 | 1 | 0.110 |
Why?
|
| Microsurgery | 2 | 2011 | 84 | 0.110 |
Why?
|
| Ophthalmoscopy | 1 | 2013 | 12 | 0.110 |
Why?
|
| Eye Infections, Fungal | 1 | 2013 | 14 | 0.110 |
Why?
|
| Disease Progression | 5 | 2014 | 1531 | 0.110 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2013 | 39 | 0.110 |
Why?
|
| Leukocyte Count | 1 | 2013 | 220 | 0.110 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 21 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 106 | 0.110 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2013 | 48 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2011 | 81 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 6501 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 70 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2013 | 211 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 279 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1373 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 141 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2013 | 173 | 0.110 |
Why?
|
| Neurosurgical Procedures | 2 | 2012 | 213 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 295 | 0.110 |
Why?
|
| Paternalism | 1 | 2012 | 24 | 0.110 |
Why?
|
| Trans-Activators | 2 | 2013 | 429 | 0.110 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 1753 | 0.110 |
Why?
|
| Adenocarcinoma | 4 | 2012 | 1169 | 0.110 |
Why?
|
| Rare Diseases | 1 | 2012 | 59 | 0.110 |
Why?
|
| Decision Making | 2 | 2022 | 642 | 0.110 |
Why?
|
| Cell Separation | 3 | 2012 | 196 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 860 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2012 | 81 | 0.100 |
Why?
|
| Prevalence | 2 | 2013 | 1239 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 1996 | 696 | 0.100 |
Why?
|
| Cross-Priming | 1 | 2012 | 48 | 0.100 |
Why?
|
| Drosophila Proteins | 1 | 1996 | 488 | 0.100 |
Why?
|
| Brachial Artery | 1 | 2011 | 36 | 0.100 |
Why?
|
| Genes, p16 | 1 | 2011 | 11 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 376 | 0.100 |
Why?
|
| Visual Acuity | 2 | 2009 | 194 | 0.100 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.100 |
Why?
|
| Meningioma | 1 | 2011 | 60 | 0.100 |
Why?
|
| Graft vs Tumor Effect | 1 | 2010 | 25 | 0.100 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2011 | 118 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 58 | 0.100 |
Why?
|
| Cellular Senescence | 1 | 2011 | 94 | 0.100 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 31 | 0.100 |
Why?
|
| Carotid Arteries | 1 | 2011 | 127 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2022 | 1804 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 88 | 0.090 |
Why?
|
| Aorta, Abdominal | 1 | 2010 | 60 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2012 | 170 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 1197 | 0.090 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2009 | 4 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2012 | 291 | 0.090 |
Why?
|
| Intraoperative Complications | 2 | 2011 | 185 | 0.090 |
Why?
|
| Chemokines, CXC | 2 | 2007 | 21 | 0.090 |
Why?
|
| Cell Count | 2 | 2007 | 195 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 321 | 0.090 |
Why?
|
| Neuropsychological Tests | 3 | 2018 | 502 | 0.090 |
Why?
|
| Homeostasis | 1 | 2012 | 409 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2010 | 94 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2009 | 28 | 0.090 |
Why?
|
| Pediatric Nursing | 1 | 2009 | 6 | 0.090 |
Why?
|
| Oncology Nursing | 1 | 2009 | 8 | 0.090 |
Why?
|
| Laser Coagulation | 1 | 2009 | 54 | 0.090 |
Why?
|
| Hyperoxia | 1 | 2009 | 34 | 0.090 |
Why?
|
| Age of Onset | 2 | 2020 | 310 | 0.090 |
Why?
|
| Parents | 1 | 2012 | 272 | 0.090 |
Why?
|
| Total Quality Management | 1 | 2009 | 34 | 0.090 |
Why?
|
| Etoposide | 2 | 2019 | 196 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2013 | 673 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 295 | 0.090 |
Why?
|
| Genome, Human | 1 | 2014 | 756 | 0.090 |
Why?
|
| Medical Order Entry Systems | 1 | 2009 | 25 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2007 | 70 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 114 | 0.090 |
Why?
|
| Calcinosis | 1 | 2010 | 224 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2010 | 177 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 728 | 0.080 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 19 | 0.080 |
Why?
|
| Capillaries | 1 | 2009 | 91 | 0.080 |
Why?
|
| Fluid Therapy | 1 | 2009 | 50 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 322 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 378 | 0.080 |
Why?
|
| Smoking | 1 | 2013 | 609 | 0.080 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 60 | 0.080 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 1208 | 0.080 |
Why?
|
| Teratoma | 1 | 2008 | 50 | 0.080 |
Why?
|
| Chondroitin | 1 | 2008 | 19 | 0.080 |
Why?
|
| Uveitis, Anterior | 1 | 2008 | 5 | 0.080 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2008 | 11 | 0.080 |
Why?
|
| Foreign-Body Reaction | 1 | 2008 | 11 | 0.080 |
Why?
|
| Cultural Characteristics | 1 | 2008 | 19 | 0.080 |
Why?
|
| Social Values | 1 | 2008 | 44 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2011 | 710 | 0.080 |
Why?
|
| Photography | 1 | 2008 | 37 | 0.080 |
Why?
|
| Hyaluronic Acid | 1 | 2008 | 49 | 0.080 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 332 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 456 | 0.080 |
Why?
|
| Endothelium, Corneal | 1 | 2007 | 19 | 0.080 |
Why?
|
| Quinolones | 1 | 2007 | 60 | 0.080 |
Why?
|
| Corneal Diseases | 1 | 2007 | 32 | 0.080 |
Why?
|
| Regeneration | 1 | 2008 | 143 | 0.080 |
Why?
|
| Fetal Blood | 1 | 2007 | 90 | 0.080 |
Why?
|
| Anisotropy | 2 | 2018 | 62 | 0.070 |
Why?
|
| Patient Safety | 2 | 2019 | 212 | 0.070 |
Why?
|
| Ovary | 1 | 2008 | 257 | 0.070 |
Why?
|
| Adult Stem Cells | 1 | 2007 | 30 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2011 | 1458 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 5 | 2014 | 3092 | 0.070 |
Why?
|
| Brain Edema | 1 | 2007 | 50 | 0.070 |
Why?
|
| Macrophages | 1 | 2010 | 554 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2019 | 751 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2008 | 220 | 0.070 |
Why?
|
| CD146 Antigen | 1 | 2006 | 4 | 0.070 |
Why?
|
| Poverty | 1 | 2008 | 173 | 0.070 |
Why?
|
| Optic Disk | 1 | 2006 | 13 | 0.070 |
Why?
|
| Germinoma | 1 | 2006 | 3 | 0.070 |
Why?
|
| Social Support | 1 | 2008 | 193 | 0.070 |
Why?
|
| Macula Lutea | 1 | 2006 | 19 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 683 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2014 | 348 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2012 | 1538 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2008 | 669 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2007 | 218 | 0.070 |
Why?
|
| Mice, Knockout | 4 | 2014 | 1924 | 0.070 |
Why?
|
| Rats | 5 | 2009 | 3990 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 567 | 0.070 |
Why?
|
| Quantum Dots | 1 | 2005 | 19 | 0.070 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2005 | 14 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 927 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2009 | 329 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 1620 | 0.060 |
Why?
|
| Lung | 2 | 2009 | 1170 | 0.060 |
Why?
|
| Bone Marrow Purging | 1 | 2004 | 7 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2020 | 288 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 318 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2009 | 394 | 0.060 |
Why?
|
| Body Weights and Measures | 1 | 2004 | 27 | 0.060 |
Why?
|
| Receptor, trkC | 1 | 2004 | 2 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2006 | 207 | 0.060 |
Why?
|
| Necrosis | 2 | 2018 | 204 | 0.060 |
Why?
|
| Electroporation | 1 | 2004 | 55 | 0.060 |
Why?
|
| Physicians | 1 | 2012 | 673 | 0.060 |
Why?
|
| Translocation, Genetic | 2 | 2019 | 265 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2022 | 970 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2003 | 387 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 1937 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2018 | 285 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 999 | 0.060 |
Why?
|
| Pluripotent Stem Cells | 1 | 2003 | 31 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 269 | 0.060 |
Why?
|
| Centrosome | 1 | 2003 | 22 | 0.060 |
Why?
|
| Epithelium, Corneal | 1 | 2002 | 12 | 0.060 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2002 | 14 | 0.060 |
Why?
|
| Cell Line | 4 | 2007 | 2468 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2705 | 0.060 |
Why?
|
| Iris Diseases | 1 | 2002 | 6 | 0.060 |
Why?
|
| Zebrafish Proteins | 1 | 2004 | 144 | 0.060 |
Why?
|
| Norethindrone | 1 | 2022 | 12 | 0.060 |
Why?
|
| Progestins | 1 | 2022 | 22 | 0.050 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2022 | 21 | 0.050 |
Why?
|
| Levonorgestrel | 1 | 2022 | 11 | 0.050 |
Why?
|
| Memory | 2 | 2016 | 225 | 0.050 |
Why?
|
| Artifacts | 1 | 2004 | 244 | 0.050 |
Why?
|
| Phenotype | 4 | 2011 | 2377 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 916 | 0.050 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 93 | 0.050 |
Why?
|
| Progesterone | 1 | 2022 | 110 | 0.050 |
Why?
|
| Mass Screening | 2 | 2022 | 617 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2009 | 194 | 0.050 |
Why?
|
| Autoantigens | 1 | 2003 | 127 | 0.050 |
Why?
|
| China | 1 | 2002 | 228 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 192 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2001 | 59 | 0.050 |
Why?
|
| Base Sequence | 4 | 2014 | 2330 | 0.050 |
Why?
|
| Chicago | 2 | 2017 | 1379 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2002 | 110 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 105 | 0.050 |
Why?
|
| Cysts | 1 | 2002 | 104 | 0.050 |
Why?
|
| Overweight | 1 | 2022 | 118 | 0.050 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2001 | 48 | 0.050 |
Why?
|
| Baltimore | 2 | 2013 | 36 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2019 | 299 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 262 | 0.050 |
Why?
|
| Craniotomy | 1 | 2001 | 88 | 0.050 |
Why?
|
| Sirolimus | 1 | 2022 | 169 | 0.050 |
Why?
|
| Amyloidosis | 1 | 2002 | 115 | 0.050 |
Why?
|
| Antibodies | 2 | 2008 | 350 | 0.050 |
Why?
|
| Hydrocephalus | 1 | 2001 | 101 | 0.050 |
Why?
|
| Diencephalon | 1 | 2000 | 6 | 0.050 |
Why?
|
| Bevacizumab | 3 | 2007 | 281 | 0.050 |
Why?
|
| RNA, Messenger | 5 | 2010 | 1981 | 0.050 |
Why?
|
| Time Factors | 3 | 2020 | 5209 | 0.050 |
Why?
|
| Linear Models | 2 | 2011 | 421 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2017 | 684 | 0.040 |
Why?
|
| Palliative Care | 1 | 2001 | 257 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1673 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 532 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 1998 | 8 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2014 | 458 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 111 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 1998 | 42 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2018 | 5 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 13 | 0.040 |
Why?
|
| Reoperation | 1 | 2001 | 597 | 0.040 |
Why?
|
| Cryptosporidiosis | 1 | 1998 | 6 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2018 | 121 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 702 | 0.040 |
Why?
|
| Florida | 1 | 2018 | 54 | 0.040 |
Why?
|
| Prednisone | 1 | 2019 | 258 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 148 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2018 | 37 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 28 | 0.040 |
Why?
|
| Texas | 1 | 2018 | 101 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 70 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2005 | 1540 | 0.040 |
Why?
|
| Photons | 1 | 2018 | 46 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 79 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 295 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1823 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2012 | 58 | 0.040 |
Why?
|
| Uncertainty | 1 | 2018 | 71 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 521 | 0.040 |
Why?
|
| Behavior | 1 | 2018 | 85 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2426 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 3030 | 0.040 |
Why?
|
| Blood Proteins | 1 | 1998 | 144 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2012 | 165 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 1998 | 89 | 0.040 |
Why?
|
| White Matter | 1 | 2018 | 80 | 0.040 |
Why?
|
| Hypoxia | 1 | 2022 | 641 | 0.040 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 1996 | 4 | 0.040 |
Why?
|
| Helix-Turn-Helix Motifs | 1 | 1996 | 7 | 0.040 |
Why?
|
| Chemokine CXCL12 | 2 | 2007 | 37 | 0.040 |
Why?
|
| Cetuximab | 1 | 2017 | 113 | 0.040 |
Why?
|
| Zinc Fingers | 1 | 1996 | 56 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1996 | 72 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 146 | 0.040 |
Why?
|
| Antineoplastic Protocols | 1 | 2016 | 9 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 173 | 0.040 |
Why?
|
| Lomustine | 1 | 2016 | 26 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 1996 | 117 | 0.040 |
Why?
|
| Codon | 1 | 1996 | 124 | 0.040 |
Why?
|
| Camptothecin | 1 | 2017 | 189 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1996 | 279 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 853 | 0.030 |
Why?
|
| Rehabilitation, Vocational | 1 | 1995 | 4 | 0.030 |
Why?
|
| Affective Disorders, Psychotic | 1 | 1995 | 16 | 0.030 |
Why?
|
| Case Management | 1 | 1995 | 24 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2011 | 1041 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 178 | 0.030 |
Why?
|
| Hostility | 1 | 1995 | 24 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 963 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2893 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 170 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 1998 | 374 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1161 | 0.030 |
Why?
|
| Intestines | 1 | 1998 | 411 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1996 | 460 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 1014 | 0.030 |
Why?
|
| Cyclins | 1 | 1994 | 82 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2014 | 39 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 678 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1996 | 579 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 105 | 0.030 |
Why?
|
| Personality Disorders | 1 | 1995 | 146 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 857 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 229 | 0.030 |
Why?
|
| Safety | 1 | 2014 | 152 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 126 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2014 | 159 | 0.030 |
Why?
|
| Candida | 1 | 2013 | 17 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 171 | 0.030 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2012 | 11 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 267 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 93 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2013 | 69 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 250 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2012 | 50 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 59 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 124 | 0.030 |
Why?
|
| Drosophila | 1 | 1996 | 498 | 0.030 |
Why?
|
| Ethical Analysis | 1 | 2012 | 23 | 0.030 |
Why?
|
| Apoptosis | 2 | 2000 | 1683 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1996 | 623 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 552 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2012 | 268 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1961 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2011 | 40 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 93 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2012 | 207 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 49 | 0.030 |
Why?
|
| Manometry | 1 | 2011 | 43 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1135 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 273 | 0.030 |
Why?
|
| Elasticity | 1 | 2011 | 94 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 2011 | 71 | 0.030 |
Why?
|
| Vasodilation | 1 | 2011 | 96 | 0.030 |
Why?
|
| Research | 1 | 2012 | 253 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 596 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2011 | 21 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 80 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2011 | 37 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 418 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 458 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 249 | 0.020 |
Why?
|
| Proteins | 1 | 1996 | 777 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 294 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 109 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 68 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1034 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2013 | 236 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 2818 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2003 | 256 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 85 | 0.020 |
Why?
|
| Clodronic Acid | 1 | 2010 | 9 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 222 | 0.020 |
Why?
|
| Etanercept | 1 | 2010 | 32 | 0.020 |
Why?
|
| Mitosis | 1 | 2010 | 153 | 0.020 |
Why?
|
| Research Report | 1 | 2010 | 44 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 91 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 88 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 325 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 104 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 692 | 0.020 |
Why?
|
| Epigenomics | 1 | 2010 | 100 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 724 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 646 | 0.020 |
Why?
|
| Nursing Audit | 1 | 2009 | 2 | 0.020 |
Why?
|
| Nursing Evaluation Research | 1 | 2009 | 3 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 128 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2000 | 2600 | 0.020 |
Why?
|
| Medication Systems, Hospital | 1 | 2009 | 7 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 628 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2009 | 36 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 503 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2009 | 21 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 1074 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2009 | 16 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 168 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 23 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 344 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 58 | 0.020 |
Why?
|
| Safety Management | 1 | 2009 | 56 | 0.020 |
Why?
|
| Estrous Cycle | 1 | 2008 | 8 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2008 | 57 | 0.020 |
Why?
|
| Gene Expression | 2 | 2003 | 1284 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 156 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 663 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 307 | 0.020 |
Why?
|
| Program Development | 1 | 2009 | 124 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 373 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1576 | 0.020 |
Why?
|
| Electron Probe Microanalysis | 1 | 2008 | 8 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 996 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 879 | 0.020 |
Why?
|
| Neuroectodermal Tumors | 1 | 2007 | 2 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 135 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 2008 | 43 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1195 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 381 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2009 | 115 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 134 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2010 | 463 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2009 | 297 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1106 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 305 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 224 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 119 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2010 | 243 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 446 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 2062 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1513 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 3241 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 80 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1621 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1219 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2006 | 54 | 0.020 |
Why?
|
| Fluorescence | 1 | 2006 | 102 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2232 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2006 | 96 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1075 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 235 | 0.020 |
Why?
|
| Remission Induction | 1 | 2007 | 722 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2007 | 143 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2009 | 464 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 943 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1849 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2004 | 19 | 0.020 |
Why?
|
| Monocytes | 1 | 2006 | 214 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 370 | 0.020 |
Why?
|
| Cell Size | 1 | 2004 | 65 | 0.020 |
Why?
|
| Blood | 1 | 2004 | 69 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 75 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 187 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 2261 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 556 | 0.010 |
Why?
|
| Blood Cells | 1 | 2003 | 33 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2004 | 123 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 232 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2006 | 485 | 0.010 |
Why?
|
| Codon, Initiator | 1 | 2003 | 21 | 0.010 |
Why?
|
| Mesoderm | 1 | 2003 | 108 | 0.010 |
Why?
|
| Transcription Initiation Site | 1 | 2003 | 45 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 94 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 223 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2356 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 543 | 0.010 |
Why?
|
| beta Catenin | 1 | 2004 | 251 | 0.010 |
Why?
|
| Microtubules | 1 | 2003 | 119 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 316 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 393 | 0.010 |
Why?
|
| Glaucoma | 1 | 2002 | 30 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 245 | 0.010 |
Why?
|
| Drainage | 1 | 2002 | 157 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1565 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2003 | 193 | 0.010 |
Why?
|
| Melanoma | 1 | 2005 | 454 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 758 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 1056 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 712 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1990 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 275 | 0.010 |
Why?
|
| Rosette Formation | 1 | 2000 | 34 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 1204 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 1047 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 1098 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2003 | 434 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 937 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 1456 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1998 | 50 | 0.010 |
Why?
|
| Neutrophils | 1 | 2000 | 307 | 0.010 |
Why?
|
| Thalamus | 1 | 2000 | 132 | 0.010 |
Why?
|
| Cryptosporidium parvum | 1 | 1998 | 4 | 0.010 |
Why?
|
| Defensins | 1 | 1998 | 5 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1998 | 165 | 0.010 |
Why?
|
| Cattle | 1 | 1998 | 376 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 307 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 1565 | 0.010 |
Why?
|
| Zinc | 1 | 1994 | 91 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 977 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 2261 | 0.010 |
Why?
|
| Cell Division | 1 | 1994 | 696 | 0.010 |
Why?
|
| Transfection | 1 | 1994 | 896 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 2887 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 1920 | 0.000 |
Why?
|